Esta pesquisa objetivou identificar como ocorre o manejo clínico e medicamentoso da gestante com HIV nas maternidades de referência da região do Cariri. Estudo descritivo, retrospectivo, com dados de 22 prontuários e 21 fichas de notificação entre agosto de 2003 e setembro de 2007, analisados por estatística descritiva. Todas as gestantes realizaram 4 a 6 consultas de pré-natal. A maioria recebeu profilaxia com AZT; foram realizados 16 testes rápidos para o HIV. O parto cesáreo foi o mais utilizado; 17 receberam AZT intraparto e esquema completo; 9 iniciaram o AZT intravenoso antes de três horas de internação. No puerpério, sete realizaram inibição mecânica da lactação; duas, inibições hormonais; e oito, os dois métodos. Todos recém-nascidos receberam AZT oral e fórmula infantil. As maternidades investigadas seguem as orientações do MS quanto: uso de teste rápido, escolha do tipo de parto, profilaxia com AZT intravenoso, inibição da lactação e cuidados imediatos aos recém-nascidos.
8627 Background: The reported incidence of DVT-CVC is extremely variable (0.3–28.3% for symptomatic thrombosis and 27–66% for asymptomatic thrombosis). Data in regarding new catheter materials and insertion techniques are very limited. Likewise, the use of antithrombotic prophylaxis in cancer patients with a CVC remains debatable. Methods: A prospective epidemiologic study was performed, which included adult patients with active cancer and no history of venous thromboembolism, in whom a long term CVC was inserted. Patients were followed-up for 90 days and a bilateral upper extremity Doppler-ultrasound was performed on days 45±5 and 90±5. Likewise, basal blood samples were taken and have been analyzed for hypercoagulability markers and prothrombotic factors. Results: Inclusion period lasted from July 2004 until May 2005. 141 patients have completed the follow up, with a mean age of 52.1±14.3 years (range 21–87). The cumulative incidence of DVT-CVC was 14.2% (20/141): 6.4% were symptomatic (9/141) and 8.9% were asymptomatic (11/123). All thrombotic events, excluding 4 cases, occurred before day 45. Neither age, gender, type of tumor (solid or haematological cancer), tumor stage, type of CVC (Port or tunnelled), number of lumens, side of insertion, platelet count or use of antithrombotic prophylaxis were significantly associated with the incidence of DVT-CVC, although only 1/8 patients with DVT-CVC receiving antithrombotic prophylaxis (12.5%) used high risk prophylaxis. Patients with prior central catheters tended to have a greater incidence of DVT-CVC (P=0.10). None of the basal plasma markers analyzed (fibrinogen, D dimer, F VIII, proteine C resistance, prothrombin fragments 1+2, thrombin-antithrombin complex) have been significantly associated with increased risk of DVT-CVC. Conclusions: DVT-CVC is a frequent complication in cancer patients, as with solid tumors so with haematologic malignancies. The incidence of DVT-CVC seems to be specially high the first few weeks following catheter placement. None of the basal plasma markers analyzed in this study have been associated with the incidence of DVT-CVC. New studies must be performed to allow identification of at risk patients who might benefit from antithrombotic prophylaxis. No significant financial relationships to disclose.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.